– Publication details the discovery and preclinical characterization of ziftomenib, including its po

– Publication details the discovery and preclinical characterization of ziftomenib, including its po

SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b

SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and main

Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib

Kura Oncology NASDAQ: KURA presented updated results from its Phase 1 FIT-001 trial evaluating darli

– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-

– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus ca

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus ca

Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a rela

SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b

Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KO

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b

Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response r

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated an

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its p

Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI,

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

  On Tuesday, 647 companies set new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn

  Friday's session saw 104 companies set new 52-week lows.

  On Thursday, 185 companies achieved new lows for the year.

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnin

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutica

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin

  Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu

  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e

    On Friday morning, 155 companies achieved new lows for the year.